Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414075 | 0.84 | CYP1A1 (0.50) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL21178072 | 0.78 | MEN1 (0.37) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL17955163 | 0.78 | DYRK1A (0.43) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL31174981 | 0.78 | DYRK1A (0.43) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL29374267 | 0.75 | ALDH1A1 (0.53) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL1187339 | 0.75 | ALDH1A1 (0.53) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL28782140 | 0.75 | ALDH1A1 (0.33) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL23043312 | 0.75 | CYP1A1 (0.33) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL23042993 | 0.75 | ALDH1A1 (0.35) | CYP1A1CYP1B1ALDH1A1HSD17B10TSHR | |
| SCHEMBL22288139 | 0.75 | DYRK1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907387-B | Pyrimido pyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2023-11-10 | — | — | CN | claimed |
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-114907387-B | Pyrimido pyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-114907387-A | Pyrimidopyrrole KRAS inhibitor and preparation method and application thereof | 中山大学 | 2022-08-16 | — | — | CN | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP1A1 3164/4885CYP1B1 2005/4885ALDH1A1 2943/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP1A1 2994/4885CYP1B1 1814/4885ALDH1A1 2681/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP1A1 2493/4885CYP1B1 1882/4885ALDH1A1 1816/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP1A1 3645/4885CYP1B1 2581/4885ALDH1A1 1957/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP1A1 3711/4885CYP1B1 2684/4885ALDH1A1 2055/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP1A1 2994/4885CYP1B1 1814/4885ALDH1A1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.